Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine131-tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 55, Issue 12, 2014, Pages 2754-2760

  Olney, Harold J ^a   Freeman, Marni A ^b   Stewart, Douglas A ^c   Mangel, Joy E ^d   White, Darrell J ^e   Elia Pacitti, Julia O ^b  

^a NOTRE DAME HOSPITAL   (Canada)

^b GLAXOSMITHKLINE   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Durable response; Indolent NHL; Quality of life; Radioimmunotherapy; Tositumomab

Indexed keywords

HEMOGLOBIN; LACTATE DEHYDROGENASE; RITUXIMAB; THYROTROPIN; TOSITUMOMAB; TOSITUMOMAB I 131; IODINE-131 ANTI-B1 ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BACKACHE; BACTEREMIA; BODY MASS; BODY SURFACE; CANCER GRADING; CANDIDIASIS; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DYSPNEA; FATIGUE; FEMALE; FEVER; FUNCTIONAL STATUS; GASTROINTESTINAL HEMORRHAGE; HEART LEFT VENTRICLE FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSOMNIA; LONG TERM SURVIVAL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PATIENT HISTORY OF RADIOTHERAPY; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PRURITUS; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; THROMBOCYTE COUNT; THYROID FUNCTION; TREATMENT RESPONSE; VIREMIA; VOMITING; WELLBEING; CANADA; CLINICAL TRIAL; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MORTALITY; PROGNOSIS; RETREATMENT; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CANADA; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; RETREATMENT; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84919425577     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.894190     Document Type: Article

References (26)

1. Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma:prognostic factors for response and survival. J Clin Oncol 1986;4:1470-1480.
2. Fisher RI. Overview of non-Hodgkin's lymphoma. Biology, staging and treatment. Semin Oncol 2003;30:3-9.
3. Horning SJ, Younes A, Jain V, et al. efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005;23:712-719.
4. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441-449.
5. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-3928.
6. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000;18:1316-1323.
7. Davies AJ, Rohatiner AZ, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1469-1479.
8. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 1259-1266.
9. Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes signif cantly to the activity of radioimmunotherapy. Clin Cancer Res 2004; 10: 7792-7798.
10. Buchegger F, Antonescu C, Delaloye AB, et al. Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer 2006;94:1770-1776.
11. Buchegger F, Antonescu C, Helg C, et al. Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission. J Nucl Med 2011; 52:896-900.
12. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 7565-7573.
13. â therapy (tositumomab and iodine I 131 tositumomab). Mississauga, ON: GlaxoSmithKline, Inc.; 20 Dec 2007.
14. Cheson BD, Horning SJ, Coifer B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-1253.
15. Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 1009: 1804-1810.
16. Wiseman GA, Witzig TE. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2005; 20: 185-188.
17. Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995;13:140-147.
18. Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 2005;105:4576-4582.
19. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-1265.
20. Gleissner B, Küppers R, Siebert R, et al. Report of a workshop on malignant lymphoma: a review of molecular and clinical risk Profiling. Br J Haematol 2008; 142: 166-178.
21. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2:A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555-4562.
22. Calle EE, Rodriguez C, Walker-Turmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638.
23. Guiu B, Petit JM, Bonnetain F, et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut 2010;59:341-347.
24. Klaasen R, Cantaert T, Wijbrandts CA, et al. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to inf iximab in rheumatoid arthritis:An exploratory study. Rheumatology (Oxford) 2011;50:1487-1493.
25. Portugal RD. Obesity and dose individualization in cancer chemotherapy: the role of body surface area and body mass index. Med Hypotheses 2005;65:748-751.
26. Hunter RJ, Nano MA, Taker PH, et al. Dosing chemotherapy in obese patients actual versus assigned body surface area (BSA). Cancer Treat Rev 2009; 35: 69-78.